Hutajulu Susanna Hilda, Paramita Dewi Kartikawati, Santoso Joyo, Sani Muhammad Ivan Aulia, Amalia Aghnia, Wulandari Gatri, Ghozali Ahmad, Kurnianda Johan
Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr Sardjito Hospital, Yogyakarta, Indonesia.
Department of Histology and Cell Biology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
J Gastrointest Oncol. 2018 Dec;9(6):1099-1108. doi: 10.21037/jgo.2018.07.01.
Vascular endothelial growth factor-A (VEGF-A) has been observed as the predominant angiogenic factor in colorectal cancer (CRC) and the assessment of microvessel density (MVD) has been used to quantify tumor neoangiogenesis. This study aimed to determine clinicopathological and prognostic significance of both angiogenic markers in the local CRC patients.
We analyzed tissue samples obtained from 81 cases with CRC. VEGF-A expression and MVD counts were immunohistochemically detected using anti VEGF-A and CD31. The assessments of both markers were classified as low and high. Correlation between VEGF-A expression and MVD value and clinicopathological characteristics were examined using Chi-square test. The overall survival (OS) was plotted using the Kaplan-Meier method.
High VEGF-A expression was found more frequently in the rectal location (P=0.042) and T4 tumors (P=0.041) compared to their counterparts. Older patients tended to show a higher MVD value compared to younger cases (P=0.062). In addition, survival analysis showed that males had a worse OS compared to females (P=0.029), and VEGF-A expression and MVD count did not correlate with patients' survival.
There were significant differences of VEGF-A expression according to tumor location and T invasion. Sex, but not angiogenic markers, had an influence on the survival of CRC patients.
血管内皮生长因子-A(VEGF-A)被认为是结直肠癌(CRC)中主要的血管生成因子,微血管密度(MVD)的评估已被用于量化肿瘤新生血管。本研究旨在确定这两种血管生成标志物在局部CRC患者中的临床病理及预后意义。
我们分析了81例CRC患者的组织样本。使用抗VEGF-A和CD31免疫组化检测VEGF-A表达和MVD计数。两种标志物的评估分为低和高。使用卡方检验检查VEGF-A表达与MVD值及临床病理特征之间的相关性。采用Kaplan-Meier法绘制总生存期(OS)曲线。
与其他部位相比,VEGF-A高表达在直肠部位(P = 0.042)和T4期肿瘤(P = 0.041)中更常见。老年患者的MVD值往往比年轻患者高(P = 0.062)。此外,生存分析表明,男性的OS比女性差(P = 0.029),且VEGF-A表达和MVD计数与患者生存无关。
VEGF-A表达根据肿瘤位置和T分期有显著差异。性别而非血管生成标志物对CRC患者的生存有影响。